Incyte reports strong Q3 sales and raises 2026 outlook despite Vega-related loss

Incyte reported third-quarter 2026 revenue of $1.56 billion, up 14% year over year, while a $1.23 billion Vega Therapeutics acquisition-related research charge produced a GAAP net loss of $784.8 million, or $3.86 per share. Adjusted net loss was $730.80 million, or $3.60 per share. The company raised full-year 2026 total net-sales guidance to $5.21 billion-$5.30 billion, with growth led by Opzelura and its hematology and oncology portfolio.

The acquisition charge depressed reported earnings, but it was tied to a one-time transaction expense, while higher sales guidance improves the company’s near-term revenue outlook. Incyte expects its expanding commercial portfolio and pipeline to support growth as Jakafi approaches generic competition.

  • 1Third-quarter revenue increased 14% year over year to $1.56 billion.
  • 2Incyte recorded a third-quarter GAAP net loss of $784.80 million, or $3.86 per share.
  • 3The Vega Therapeutics transaction generated a one-time $1.23 billion acquired in-process research and development expense.
  • 4Adjusted third-quarter net loss was $730.80 million, or $3.60 per share.
  • 5Full-year 2026 total net-sales guidance rose to $5.21 billion-$5.30 billion from $5.13 billion-$5.26 billion.
  • 6Core business net sales excluding Jakafi reached $490 million, a 37% year-over-year increase.
  • Consensus EPS estimates vary across the materials, with different sources reporting both a beat and a miss against their respective estimates.

Sources